AAPS PharmSciTech

, Volume 5, Issue 2, pp 77–82 | Cite as

Gastroretentive drug delivery system of ranitidine hydrochloride: Formulation and in vitro evaluation

  • Brijesh S. DaveEmail author
  • Avani F. Amin
  • Madhabhai M. Patel


The purpose of this research was to prepare a gastroretentive drug delivery system of ranitidine hydrochloride. Guar gum, xanthan gum, and hydroxypropyl methylcellulose were evaluated for gel-forming properties. Sodium bicarbonate was incorporated as a gas-generating agent. The effects of citric acid and stearic acid on drug release profile and floating properties were investigated. The addition of stearic acid reduces the drug dissolution due to its hydrophobic nature. A 32 full factorial design was applied to systemically optimize the drug release profile. The amounts of citric acid anhydrous (X1) and stearic acid (X2) were selected as independent variables. The times required for 50% (t50) and 80% drug dissolution (t80), and the similarity factor f2 were selected as dependent variables. The results of the full factorial design indicated that a low amount of citric acid and a high amount of stearic acid favors sustained release of ranitidine hydrochloride from a gastroretentive formulation. A theoretical dissolution profile was generated using pharmacokinetic parameters of ranitidine hydrochloride. The similarity factor f2 was applied between the factorial design batches and the theoretical dissolution profile. No significant difference was observed between the desired release profile and batches F2, F3, F6, and F9. Batch F9 showed the highest f2 (f2=75) among all the batches, and this similarity is also reflected in t50 (∼214 minutes) and t80 (∼537 minutes) values. These studies indicate that the proper balance between a release rate enhancer and a release rate retardant can produce a drug dissolution profile similar to a theoretical dissolution profile.


ranitidine hydrochloride gastroretentive floating drug delivery sustained release 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Histamine H2 antagonists. In: Drug Facts and Comparisons. 16th ed. St Louis, MO: Wolters Kluwer Co; 1996:1862–1876.Google Scholar
  2. 2.
    Somade S, Singh K. Comparative evaluation of wet granulation and direct compression methods for preparation of controlled release Ranitidine HCL tablets. Indian J Pharm Sci. 2002;64:285.Google Scholar
  3. 3.
    Lauritsen K. Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases. Clin Pharmacokinet. 1990;19:11–31, 94–125.CrossRefGoogle Scholar
  4. 4.
    Grant S. Ranitidine: an updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in peptic ulcer and other allied diseases. Drugs. 1989;37:801–870.CrossRefGoogle Scholar
  5. 5.
    Basit A, Lacey L. Colonic metabolism of ranitidine: implications for its delivery and absorption. Int J Pharm. 2001;227(1–2):157–165.CrossRefGoogle Scholar
  6. 6.
    Coffin M, Parr A. Ranitidine solid dosage form. US Patent 5 407 687. April 18, 1995.Google Scholar
  7. 7.
    Singh B, Kim K. Floating drug delivery systems: an approach to oral controlled drug delivery via gastric retention. J Control Release. 2000;63:235–259.CrossRefGoogle Scholar
  8. 8.
    Chawla G, Bansal A. A means to address regional variability in intestinal drug absorption. Pharm Tech. 2003;27:50–68.Google Scholar
  9. 9.
    Rosa M, Zia H, Rhodes T. Dosing and testing in-vitro of a bioadhesive and floating drug delivery system for oral application. Int J Pharm. 1994;105:65–70.CrossRefGoogle Scholar
  10. 10.
    Korsemeyer R, Gurny R, Peppas N. Mechanisms of solute release from porous hydrophilic polymers. Int J Pharm. 1983;15:25–35.CrossRefGoogle Scholar
  11. 11.
    Wagner JG. Interpretation of percent dissolved-time plots derived from in vitro testing of conventional tablets and capsules. J Pharm Sci. 1969;58:1253–1257.CrossRefGoogle Scholar
  12. 12.
    Gibaldi M, Feldman S. Establishment of sink conditions in dissolution rate determinations: theoretical considerations and application to nondisintegrating dosage forms. J Pharm Sci. 1967;56:1238–1242.CrossRefGoogle Scholar
  13. 13.
    Higuchi T. Rate of release of medicaments from ointment bases containing drugs in suspension. J Pharm Sci. 1961;50:874–875.CrossRefGoogle Scholar
  14. 14.
    Higuchi T. Mechanism of sustained-action medication: theoretical analysis of rate of release of solid drugs dispersed in solid matrices. J Pharm Sci. 1963;52:1145–1149.CrossRefGoogle Scholar
  15. 15.
    Cobby J, Mayersohn M, Walker GC. Influence of shape factors on kinetics of drug release from matrix tablets. II. Experimental. J Pharm Sci. 1974;63:732–737.CrossRefGoogle Scholar
  16. 16.
    Hixson AW, Crowell JH. Dependence of reaction velocity upon surface and agitation. Ind Eng Chem. 1931;23:923–931.CrossRefGoogle Scholar
  17. 17.
    Peppas NA. Analysis of Fickian and non-Fickian drug release from polymers. Pharm Acta Helv. 1985;60:110–111.Google Scholar
  18. 18.
    Harland RS, Gazzaniga A, Sangalli ME, Colombo P, Peppas NA. Drug/polymer matrix swelling and dissolution. Pharm Res. 1988;5:488–494.CrossRefGoogle Scholar
  19. 19.
    Langenbucher F. Linearization of dissolution rate curves by the Weibull distribution. J Pharm Pharmacol. 1988;24:979–981.Google Scholar
  20. 20.
    Goldsmith JA, Randall N, Ross SD. On methods of expressing dissolution rate data. J Pharm Pharmacol. 1978;30:347–349.Google Scholar
  21. 21.
    Romero P, Costa JB, Chulia D. Statistical optimization of a controlled release formulation obtained by a double compression process: application of a Hadamard matrix and a factorial design. In: Wells JI, Rubinstein MH, Horwood E, eds. Pharmaceutical Technology, Controlled Drug Release. Vol 2. New York, NY: Ellis Harwood; 1991:44–58.Google Scholar
  22. 22.
    Vudathala GK, Rogers JA. Dissolution of fludrocortisone from phospholipid coprecipitates. J Pharm Sci. 1992;81(3):282–286.CrossRefGoogle Scholar
  23. 23.
    Bamba M, Puisieusx F. Release mechanisms in gel forming sustained release preparation. Int J Pharm. 1979;2:307–315.CrossRefGoogle Scholar
  24. 24.
    Whitehead L, Fell J, Collett J, Sharma H, Smith A. Floating dosage forms: an in vivo study demonstrating prolonged gastric retention. J Control Release. 1998;55:3–12.CrossRefGoogle Scholar
  25. 25.
    Eyjolfsson R. Ramtidine HCl: tablet film coating acidity and discoloration. Drug Dev Ind Pharm. 2000;26:693–694.CrossRefGoogle Scholar
  26. 26.
    Guidance for Industry SUPAC-MR. Modified Release Solid Oral Dosage Forms Scale-Up and Postapproval Changes: Chemistry, Manufacturing, and Controls; In Vitro Dissolution Testing and In Vivo Bioequivalence Documentation. Available at: Scholar
  27. 27.
    Moore J, Flanner H. Mathematical comparison of dissolution profiles. Pharm Tech. 1996;20:64–74.Google Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2004

Authors and Affiliations

  • Brijesh S. Dave
    • 1
    Email author
  • Avani F. Amin
    • 1
  • Madhabhai M. Patel
    • 1
  1. 1.Shree S. K. Patel College of Pharmaceutical Education & ResearchGanpat VidyanagarIndia

Personalised recommendations